NTRK1 fusion
|
Spindle Cell Sarcoma
|
NTRK1 fusion
|
Spindle Cell Sarcoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Spindle Cell Sarcoma
|
NTRK3 fusion
|
Spindle Cell Sarcoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
KRAS G12V
|
Spindle Cell Sarcoma
|
KRAS G12V
|
Spindle Cell Sarcoma
|
BAL3833 Sensitive: C3 – Early Trials
|
BAL3833 Sensitive: C3 – Early Trials
|
SMARCB1 negative
|
Spindle Cell Sarcoma
|
SMARCB1 negative
|
Spindle Cell Sarcoma
|
tazemetostat Sensitive: C3 – Early Trials
|
tazemetostat Sensitive: C3 – Early Trials
|
TPM3-NTRK1 fusion
|
Spindle Cell Sarcoma
|
TPM3-NTRK1 fusion
|
Spindle Cell Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
KIAA1549-BRAF fusion + PTEN deletion
|
Spindle Cell Sarcoma
|
KIAA1549-BRAF fusion + PTEN deletion
|
Spindle Cell Sarcoma
|
bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies
|
bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies
|
QKI-RAF1 fusion
|
Spindle Cell Sarcoma
|
QKI-RAF1 fusion
|
Spindle Cell Sarcoma
|
trametinib Sensitive: C4 – Case Studies
|
trametinib Sensitive: C4 – Case Studies
|
QKI-RAF1 fusion
|
Spindle Cell Sarcoma
|
QKI-RAF1 fusion
|
Spindle Cell Sarcoma
|
temozolomide + irinotecan Resistant: C4 – Case Studies
|
temozolomide + irinotecan Resistant: C4 – Case Studies
|